Molecular motion in crown ethers. Application of 13C and 2H NMR to the study of 4-carboxybenzo-24-crown-8 ether and its KNCS complex in solution and in the solid phase
The present invention relates to new CGRP-antagonists of general formula I
wherein R1, R2, R3, Ra, Rb, Rc, X, Y and Z are defined as mentioned hereinafter, the individual diastereomers, the individual enantiomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.
APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
申请人:AbbVie Inc.
公开号:US20150299197A1
公开(公告)日:2015-10-22
Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
申请人:AbbVie Inc.
公开号:US10081628B2
公开(公告)日:2018-09-25
Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds. One embodiment of such compounds is 4-(4-[2-(4-chloro-2-fluorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide.